Friday, November 13, 2026

Grinding Ball Failures Highlight the Importance of Identifying Underlying Operational Factors

Jinan City, Shandong Province, China - November 13, 2026 -

1. Breakage

A ball that splits into pieces with a flat, bright fracture rarely died of wear. Look for quench cracks, core hardness run too high for the load, or inclusions in the bar stock. To test, section the ball and measure core hardness away from the break.

2. Spalling

Flakes peel off the surface while the ball keeps its shape. This usually means a mismatch between surface hardness and the support beneath it. Because surface hardness still reads normal, incoming inspection tends to miss it.

1.jpg

3. Loss of shape

Flattened or oval balls point to under-tempering, or to large diameters that never hardened through. Core cooling slows sharply as diameter grows, so one treatment window will not cover 65 mm and 125 mm alike.

2.jpg

4. Rising consumption, no broken balls

This is the pattern most often blamed on the supplier. Check the make-up charge size distribution, filling degree, ore blend and liner profile first. Replacing the media here usually fixes nothing.

It is also why Junda publishes core hardness by diameter rather than a single figure for the whole range. For its B3 forged line: 65–125 mm, surface hardness 59–63 HRC, core hardness 53–62 HRC depending on diameter, impact toughness 12 J/cm², breakage below 1 per cent. These figures apply to that line only.

The full guide, including a failure-identification flowchart and an incoming inspection sheet, is available on request.

About us

Since its inception in 2005, Jinan Junda Industrial Technology Co., LTD has established itself as a premier, globally-oriented enterprise dedicated to the advanced research, development, high-precision manufacturing, and comprehensive distribution of premium Forged Steel Balls, Cast Steel Balls, and specialized Steel Rods. Strategically headquartered in the industrial hub of Jinan, our facility benefits from a sophisticated logistics infrastructure that ensures seamless and efficient transportation access to major ports and international markets.

Media Contact
Company Name: JINAN JUNDA INDUSTRIAL TECHNOLOGY CO., LTD
Contact Person: Media Relations
Email:Send Email
Phone: 0086-15806668333
Address:OUYADAGUAN, Shizhong District
City: Jinan
State: Shandong
Country: China
Website: https://www.blastany.com/

Top 5 Medical Uniform Manufacturers in China for OEM and Bulk Orders

Top 5 Medical Uniform Manufacturers in China for OEM and Bulk Orders
OEM medical uniforms from Sanxia

Chengdu, Sichuan, China - November 13, 2026 - Top 5 Medical Uniform Manufacturers in China for OEM and Bulk Orders

Choosing among medical uniform manufacturers in China requires more than comparing a few scrub-set photos. Hospitals need consistent sizing and dependable replenishment; distributors need repeatable specifications; private-label brands may need pattern development, fabric options, and branded packaging. Five manufacturers worth evaluating are Sanxia Workwear, LANO Wear, Raise Apparel, Xiangfeng Medical Uniform, and Guangzhou Hanguang Fashion. Each serves a different combination of healthcare apparel and customization needs.

This is an editorial shortlist, not a measured ranking of factory performance or customer satisfaction. The companies were selected for identifiable medical-uniform products, published manufacturing or development capabilities, and relevance to international business buyers. A purchasing decision should still depend on approved samples, documented requirements, and order-specific verification.

What Should Buyers Look for in a Chinese Medical Uniform Manufacturer?

The right supplier should fit the intended garment and the buying model. Standard scrub sets for a clinic, custom nurse uniforms for a distributor, and a coordinated lab-coat program may involve different fits, fabrics, trim details, and packaging. Check that a candidate can make the exact items you need rather than treating all healthcare workwear as interchangeable.

A useful comparison covers five areas: relevant product range, OEM or private-label scope, development and sampling, production-quality controls, and the ability to reproduce an approved garment for later orders. Published capacities and turnaround estimates can help screen suppliers, but they are not substitutes for a confirmed production schedule or purchase specification.

Which Five Medical Uniform Manufacturers in China Merit a Closer Look?

1. Sanxia Workwear — Multi-Category Healthcare Uniforms and OEM Development

Sanxia Workwear, operated by Chengdu Sanxia Technology Co., Ltd., manufactures professional uniforms for medical, food-processing, electronics, and other workplace applications. Its healthcare assortment includes scrub tops, scrub pants, complete scrub sets, lab coats, scrub caps, and related garments. Buyers can review the medical uniform range to compare practical styles for hospitals, clinics, and dental teams.

Sanxia integrates design discussion, fabric and trim selection, pattern development, sampling, garment production, inspection, and packing. The company states that its manufacturing operation includes a 4,000-square-meter facility and more than 200 employees. Its published OEM service supports customer designs and logo treatments such as embroidery, printing, and woven labels. These capabilities are especially relevant when departments need coordinated garments rather than a one-style commodity purchase.

Its stated minimum is 100 sets for qualifying orders, subject to the style, color, and size arrangement described in its FAQ. Buyers should confirm the applicable minimum and any customization conditions for their selected garment. Sanxia is a practical option for teams balancing healthcare uniforms with related workplace apparel and for distributors developing repeat-order programs.

Official website: https://www.sxuniform.com/

2. LANO Wear — Fashion Scrubs and Fabric-Driven Custom Collections

LANO Wear is a Guangzhou-based producer of custom medical scrubs, lab coats, and healthcare uniforms. Its catalog distinguishes fashion scrubs from industrial-laundry uniforms and also includes white coats and antistatic lab coats. That distinction matters to buyers because a stylish retail scrub collection and a uniform intended for frequent institutional laundering may require different design priorities.

LANO presents fabric sourcing, pattern and sample development, embroidery, printing, functional-material options, quality checks, and packing as part of its custom-production service. Its public specifications include polyester-rayon-spandex and polyester-cotton fabric options, but a buyer should confirm the actual composition, weight, finish, and wash behavior for each quoted style.

The company publishes an MOQ of 600 sets per style, with a minimum of 150 sets per color, and indicates typical sample and production schedules. Those are useful planning references, not guarantees for every order. LANO is worth comparing for buyers building a cohesive custom collection with distinct fabrics, fit requirements, and branding details.

Official website: https://lanowear.com/

3. Raise Apparel — Private-Label Scrubs and Repeatable Product Specifications

Raise Apparel focuses on medical scrubs and uniforms for brands, distributors, and healthcare teams. Based in Guangzhou, it lists scrub sets, tops, pants, jogger styles, lab coats, and nurse caps, as well as hospital and medical-school uniform programs. Its narrower healthcare focus can simplify discussions about scrub styling, fit, labels, and coordinated sets.

The company offers OEM, private-label, and cut-make-trim discussions supported by production references, sampling, fabric review, and bulk manufacturing. It publishes workshop photos and videos covering cutting, sewing, finishing, and packing. These materials provide a useful starting point, although buyers should still request evidence tied to their own production order.

Raise is particularly relevant when an importer needs a technical pack, approved size chart, private labels, carton assortments, and a clear reference for reorders. Ask how the supplier records revisions to fabric, garment measurements, artwork, and packing details between the first order and replenishment.

Official website: https://www.raiseapparel.com/

4. Xiangfeng Medical Uniform — Department-Specific Uniform Programs

Guangzhou Xiangfeng Garment Company offers medical scrubs, nurse uniforms, doctor uniforms, lab coats, and customized healthcare garments. Its published manufacturing information describes production operations in Henan alongside Guangzhou-based quality-control, packing, and order coordination. Confirming the actual production location is especially useful when buyers must document origin and arrange inspections.

Xiangfeng lists polyester-rayon-spandex fabric options alongside polyester-cotton materials for institutional workwear. It also describes embroidery, printing, size inspection, sewing checks, and final pre-packing inspection. The company's published MOQ is 100 pieces, with sample and bulk-production timing dependent on the order specification.

This supplier suits buyers who need distinct garment groups for clinical roles rather than a single universal scrub style. During sampling, review separate fit and size requirements for nursing, physician, and laboratory garments; verify whether any additional protective-performance claims are supported by product-specific evidence.

Official website: https://xiangfenguniform.com/

5. Guangzhou Hanguang Fashion — Healthcare Uniforms Within a Wider Uniform Program

Guangzhou Hanguang Fashion Co., Ltd. manufactures multiple uniform categories, including hospital, school, hotel, retail, and other professional apparel. The company describes an in-house production operation covering pattern development, cutting, sewing, finishing, and packaging. Its broader range can be useful to buyers managing uniforms across healthcare and adjacent service departments.

Hanguang offers OEM and ODM customization involving garment fabrics, size grading, color selection, logo embroidery or printing, and branded packaging. Its website describes an 8,000-square-meter factory and design-to-production support. Verify which medical styles are currently available and request actual garment samples before assuming that a broader corporate-uniform portfolio meets clinical requirements.

This is a supplier to consider when a hospital group, purchasing agent, or uniform distributor needs several apparel categories under one sourcing arrangement. Buyers should specify the clinical garment scope separately from general staff uniforms and avoid treating office or hospitality wear as medical protective clothing.

Official website: https://www.cnuniform.com/

How Should Buyers Compare OEM Medical Uniform Offers?

Start with fabric behavior, not fabric names alone

A fabric blend does not establish comfort or durability by itself. Ask for composition, weight, stretch direction, colorfastness expectations, and recommended laundering conditions. Review a sewn sample after the wash process intended for the end user. For a private-label collection, note the approved fabric supplier and color reference so substitutions cannot happen silently during replenishment.

Approve sizing as a system

Request finished-garment measurements, size grading, tolerances, and a physical sample in representative sizes. Scrub tops and pants may require different size mixes. For hospitals, separate the expected quantity by department, style, color, and size; for distributors, identify fast-selling sizes without assuming every market uses the same fit standard.

Make branding and packing measurable

Specify logo dimensions, position, thread or print colors, care labels, barcode needs, and packing configuration. A statement such as “custom logo available” is not enough for a purchase order. Approve embroidery or printing on the actual selected fabric, and keep the artwork version with the signed sample record.

Define inspection before production

A useful inspection plan identifies measurement checkpoints, seam workmanship, visible defects, color consistency, label accuracy, set matching, and carton quantities. Agree on acceptance criteria, inspection access, and responsibility for corrective action before cutting begins. If a garment must meet a particular protective or hygiene-related standard, request evidence for that exact product and intended use; ordinary scrubs are not automatically certified protective equipment.

Why Choose Sanxia for Custom Medical Uniform Projects?

Sanxia is particularly relevant when the order combines everyday healthcare scrubs with additional garment categories, department identification, and ongoing purchasing requirements. Its OEM customization service brings fabric selection, design confirmation, sample development, logo options, and bulk production into a defined workflow. That structure gives buyers a practical way to document decisions before committing to larger quantities.

For a new clinic chain, the conversation might begin with coordinated scrub colors and sizes. For a distributor, it may start with a branded assortment, repeatable specifications, and retail-ready labels. The appropriate next step is the same: agree on a reference sample and inspection requirements, then confirm quantities, timing, and commercial terms for the actual order. No one manufacturer is the best fit for every garment or budget.

Frequently Asked Questions

What is the difference between OEM and ODM medical uniforms?

OEM generally means producing uniforms from a buyer's designs, reference samples, or approved specifications. ODM typically includes more supplier-led design and product development. In either case, confirm pattern ownership, revision approvals, materials, labels, and which changes require another sample.

Can a Chinese manufacturer supply small medical scrub orders?

Some suppliers publish minimums around 100 sets or pieces, while others require larger style or color quantities. Minimums can change when fabric, prints, sizing, or packaging are customized. Ask for a written MOQ by style, fabric, color, and size breakdown rather than relying on a single headline number.

Are hospital scrubs the same as certified protective clothing?

No. Standard reusable scrubs are primarily work uniforms; specific protective claims require appropriate product design and supporting testing or certification. Tell the supplier whether you need ordinary daily uniforms, controlled-environment clothing, or a regulated protective garment before seeking a quote.

What should an importer include in a medical uniform RFQ?

Include the garment type, reference image or technical pack, fabric requirements, size chart, colors, estimated volume, logo and label files, packaging method, delivery destination, and target date. Request sample terms, inspection arrangements, and a repeat-order specification. A clear RFQ makes offers easier to compare across factories.

Ready to Source a Medical Uniform Collection?

A dependable order begins with the exact wearer, wash routine, garment specification, and buying volume. Compare samples from relevant manufacturers against those requirements rather than choosing on photographs or claims alone. For medical scrubs, lab coats, or coordinated staff uniforms, send Sanxia your project requirements with size quantities, fabric preferences, artwork, and delivery details to discuss an OEM-ready quotation.

About Us

Founded in 2013 and headquartered in Chengdu, Sichuan Province, Chengdu Sanxia Technology Co., Ltd. is a high-tech enterprise integrating R&D, production, warehousing, and sales. The company specializes in the development and manufacturing of protective clothing, protective footwear, protective headwear, and related supporting products.

Media Contact
Company Name: Chengdu Sanxia Technology Co., Ltd.
Contact Person: Media Relations
Email:Send Email
Country: China
Website: https://www.sxuniform.com/

Primary Sclerosing Cholangitis Drugs in Development 2026: Pipeline Therapies, Ongoing Trials, and Companies Driving Innovation | Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharma

Primary Sclerosing Cholangitis Drugs in Development 2026: Pipeline Therapies, Ongoing Trials, and Companies Driving Innovation | Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharma
(Albany, New York) - November 13, 2026: As per DelveInsight’s assessment, globally, Primary Sclerosing Cholangitis pipeline constitutes 14+ key companies continuously working towards developing 14+ Primary Sclerosing Cholangitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Primary Sclerosing Cholangitis Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Sclerosing Cholangitis Market.

 

The Primary Sclerosing Cholangitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, FDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Primary Sclerosing Cholangitis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Primary Sclerosing Cholangitis treatment therapies with a considerable amount of success over the years.

  • Primary Sclerosing Cholangitis companies working in the treatment market are HighTide Biopharma, Gilead Sciences, Immunic, Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., HighTide Biopharma, Dr. Falk Pharma, Mirum Pharmaceuticals, CymaBay Therapeutics, Ipsen, Genfit, Albireo, and others, are developing therapies for the Primary Sclerosing Cholangitis treatment

  • Emerging Primary Sclerosing Cholangitis therapies in the different phases of clinical trials are- HTD 1801, GS-9674, IMU-838, Research programme-antifibrotic therapeutics, GRI-0124, QBT-002, STP707, CS0159, CM 101, Volixibat, PLN-74809 (bexotegrast), HTD1801, Norursodeoxycholic acid, Volixibat, Seladelpar, Elafibranor, A3907, and others are expected to have a significant impact on the Primary Sclerosing Cholangitis market in the coming years.

  • In October 2026, The Phase III PSC study continued expanding its recruitment footprint across Europe, with recruitment activity recorded in Belgium, Poland, Romania, and other participating countries. The study is designed to assess whether elafibranor can improve clinical outcomes compared with placebo in adults with PSC.

  • In October 2026, Mirum Pharmaceuticals presented full results from the VISTAS trial at the American College of Gastroenterology (ACG) 2026 meeting. In patients with PSC-associated moderate-to-severe pruritus, volixibat reduced itch scores by 2.72 points compared with a 1.08-point reduction with placebo over 28 weeks. Sleep disturbance also improved. The company is targeting a potential New Drug Application (NDA) submission in the first half of 2027, following further FDA discussions.

  • In September 2026, Clinical findings published in the American Journal of Gastroenterology on September 1, 2026, evaluated nebokitug, an investigational anti-CCL24 monoclonal antibody, in patients with PSC. Results showed a generally comparable safety profile between treatment and placebo groups. Although no significant overall changes were observed in liver tests, ELF scores, or liver stiffness measurements at Week 15, a prespecified subgroup with moderate-to-advanced fibrosis demonstrated a significant reduction in liver stiffness. The findings support further investigation of nebokitug's potential antifibrotic activity.

  • In September 2026, - Norucholic acid advances through European regulatory review: Dr. Falk Pharma's norucholic acid (nor-UDCA) remained a notable late-stage PSC candidate. The European Medicines Agency's September 2026 agenda included a pre-authorisation oral explanation concerning the therapy. Nor-UDCA has completed Phase III development, but this regulatory activity does not constitute FDA approval.

  • In August 2026, Volixibat receives FDA designations: Mirum Pharmaceuticals reported that the FDA granted Breakthrough Therapy and Orphan Drug designations to volixibat for cholestatic pruritus associated with PSC. The FDA recommended a Phase III study during pre-NDA discussions, and the company planned further regulatory engagement. These designations are not marketing approvals.

  • In May 2026, Chemomab Therapeutics reported alignment with the FDA on the design of a potential Phase III registration trial for nebokitug. The investigational therapy also held FDA and EMA Orphan Drug designations and FDA Fast Track designation for PSC. These regulatory designations do not represent approval.

  • In May 2026, Mirum Pharmaceuticals’ shares rose by around 10% on Monday after the company announced that its oral IBAT inhibitor, volixibat, achieved the primary endpoint in the Phase IIb VISTAS trial involving patients with primary sclerosing cholangitis (PSC). The therapy is aimed at treating cholestatic pruritus, a common PSC symptom characterized by severe itching. According to VISTAS study investigator Kris Kowdley, current clinical options to manage this symptom are limited, and the positive results indicate a potentially meaningful advancement for PSC patients. Following these results, Mirum plans to hold a pre-NDA meeting with the FDA this summer and intends to submit a regulatory filing for volixibat in the second half of the year.

  • In March 2026, Chemomab Therapeutics Ltd. has reported its financial and operational results for the full year and fourth quarter ending December 31, 2025, along with a broader corporate update. The company focuses on advancing novel therapies for fibro-inflammatory diseases with significant unmet medical needs.

  • In September 2025, Enrollment has been finalized for the Phase 2b VISTAS trial evaluating the oral investigational therapy volixibat in patients experiencing itching related to primary sclerosing cholangitis (PSC). The study, which enrolled 182 participants, is anticipated to release top-line results between April and June of next year.

  • In August 2025, Chemomab Therapeutics reached alignment with U.S. regulators on key elements of the late-stage development of nebokitug, its investigational therapy for primary sclerosing cholangitis (PSC), while continuing to seek a strategic partner for the upcoming Phase 3 trial. In prior discussions with the FDA, it was agreed that a single Phase 3 study evaluating PSC progression-related outcomes would be adequate to support a future approval submission, provided the results demonstrate positive efficacy.

  • In June 2025, Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech developing innovative treatments for fibro-inflammatory diseases with high unmet need, announced that it has received FDA confirmation on two key development milestones as it progresses the nebokitug Phase 3 program. During the FDA End-of-Phase 2 (EOP2) review, Chemomab and the FDA discussed multiple Chemistry, Manufacturing, and Controls (CMC) topics essential for ensuring drug quality and supply consistency for late-stage development and future commercialization. The FDA expressed agreement with the CMC strategy proposed by Chemomab and its contract manufacturing partner.

  • In May 2025, Dr. Falk Pharma’s norucholic acid (NCA) has shown promising results in a Phase III study for primary sclerosing cholangitis (PSC). In the pivotal NUC-5 trial (NCT03872921), NCA achieved statistically significant improvements over placebo in meeting the combined primary goals of partially normalizing alkaline phosphatase levels—a liver enzyme associated with PSC and preventing disease progression as seen on histology. Additionally, NCA demonstrated notable benefits across several secondary endpoints, with safety and tolerability profiles comparable between the NCA and placebo groups.

  • In May 2025, Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage biopharmaceutical company focused on cardiometabolic and gastrointestinal oncology conditions, has announced promising preclinical results for Aramchol in models of primary sclerosing cholangitis (PSC). Fibroinflammatory cholangiopathies like PSC and primary biliary cholangitis (PBC) involve cholestatic damage, inflammation, and fibrosis-driven bile duct obstruction, leading to disease complications. Aramchol, a stearoyl-CoA desaturase 1 (SCD-1) inhibitor, demonstrated both preventive and therapeutic effects on biliary fibrosis in mouse models of PSC. The drug dose-dependently reduced the expression of fibrotic markers such as plasminogen activator inhibitor-1 and key hepatic stellate cell activation genes (VEGFA and PDGFB) in TGFβ-stimulated human cholangiocyte (H69) and mouse biliary epithelial cells (MLEs). Additionally, Aramchol significantly inhibited TGFβ-driven hepatic fibrosis pathways while enhancing peroxisome proliferator-activated receptor (PPAR) signaling.

 

Primary Sclerosing Cholangitis Overview

Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, which can lead to bile flow obstruction, liver damage, and eventually cirrhosis. The exact cause is unknown, but it is often associated with autoimmune conditions, particularly inflammatory bowel disease (IBD). PSC progresses slowly and may cause fatigue, itching, jaundice, and abdominal pain, but many patients remain asymptomatic in early stages. There is currently no cure, and treatment focuses on managing symptoms, preventing complications, and monitoring for liver failure or bile duct cancer.

 

Get a Free Sample PDF Report to know more about Primary Sclerosing Cholangitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-pipeline-insight

 

Emerging Primary Sclerosing Cholangitis Drugs Under Different Phases of Clinical Development Include:

  • HTD 1801: HighTide Biopharma

  • GS-9674: Gilead Sciences

  • IMU-838: Immunic

  • Research programme: antifibrotic therapeutics Engitix

  • GRI-0124: GRI Bio

  • QBT-002: Qing Bile Therapeutics

  • STP707: Sirnaomics

  • CS0159: Cascade Pharmaceuticals

  • CM 101: Chemomab Therapeutics

  • Volixibat: Mirum Pharmaceuticals

  • PLN-74809 (bexotegrast): Pliant Therapeutics, Inc.

  • HTD1801: HighTide Biopharma

  • Norursodeoxycholic acid: Dr. Falk Pharma

  • Volixibat: Mirum Pharmaceuticals

  • Seladelpar: CymaBay Therapeutics

  • Elafibranor: Ipsen/Genfit

  • A3907: Albireo/IPSEN

 

Primary Sclerosing Cholangitis Route of Administration

Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

  • Molecule Type

 

Primary Sclerosing Cholangitis Molecule Type

Primary Sclerosing Cholangitis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

 

Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment

  • Primary Sclerosing Cholangitis Assessment by Product Type

  • Primary Sclerosing Cholangitis By Stage and Product Type

  • Primary Sclerosing Cholangitis Assessment by Route of Administration

  • Primary Sclerosing Cholangitis By Stage and Route of Administration

  • Primary Sclerosing Cholangitis Assessment by Molecule Type

  • Primary Sclerosing Cholangitis by Stage and Molecule Type

 

DelveInsight's Primary Sclerosing Cholangitis Report covers around 14+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Primary Sclerosing Cholangitis product details are provided in the report. Download the Primary Sclerosing Cholangitis pipeline report to learn more about the emerging Primary Sclerosing Cholangitis therapies

 

Some of the key companies in the Primary Sclerosing Cholangitis Therapeutics Market include:

Key companies developing therapies for Primary Sclerosing Cholangitis are - HighTide Biopharma, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., Chemomab Therapeutics, CymaBay Therapeutics, Genfit, Albireo, IPSEN, and others.

 

Primary Sclerosing Cholangitis Pipeline Analysis:

The Primary Sclerosing Cholangitis pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Primary Sclerosing Cholangitis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Sclerosing Cholangitis Treatment.

  • Primary Sclerosing Cholangitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Primary Sclerosing Cholangitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Sclerosing Cholangitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Primary Sclerosing Cholangitis drugs and therapies

 

Primary Sclerosing Cholangitis Pipeline Market Drivers

  • Increasing Disease Awareness and Diagnosis: Growing awareness of primary sclerosing cholangitis (PSC), improvements in diagnostic imaging, and advancements in liver function testing are supporting early disease identification and increasing demand for effective therapies.

  • High Unmet Medical Need: The absence of widely approved disease-modifying treatments for PSC is encouraging pharmaceutical and biotechnology companies to invest in the development of innovative therapeutic candidates.

  • Advancements in Novel Therapeutic Approaches: Increasing research into FXR agonists, PPAR agonists, anti-fibrotic agents, immunomodulators, and bile acid-based therapies is expanding the PSC clinical pipeline.

  • Growing Clinical Research and R&D Investments: Rising investments in Phase II and Phase III clinical trials, along with collaborations between pharmaceutical companies and research institutions, are accelerating the development of potential PSC treatments.

  • Increasing Focus on Precision Medicine: Improved understanding of disease mechanisms, genetic factors, bile acid metabolism, and gut-liver interactions is supporting the development of targeted treatment strategies for PSC patients.

 

Primary Sclerosing Cholangitis Pipeline Market Barriers

  • Limited Understanding of Disease Pathogenesis: The complex and multifactorial nature of PSC, involving genetic, immune-mediated, and environmental factors, makes it challenging to identify effective therapeutic targets.

  • Lack of Validated Clinical Endpoints: The slow disease progression and variability in clinical manifestations make it difficult to establish reliable endpoints for evaluating treatment efficacy in PSC clinical trials.

  • High Clinical Development Costs: The rarity of PSC, limited patient populations, and requirement for long-term clinical studies increase research expenses and create challenges for pharmaceutical companies.

  • Limited Treatment Options and Disease Heterogeneity: Variations in disease severity, progression rates, and associated conditions, particularly inflammatory bowel disease, complicate treatment development and patient management.

  • Regulatory and Safety Challenges: The need to demonstrate meaningful improvements in liver function, fibrosis progression, and transplant-free survival, alongside long-term safety monitoring, can delay regulatory approvals and commercialization of emerging therapies.

 

Scope of Primary Sclerosing Cholangitis Pipeline Drug Insight

  • Coverage: Global

  • Key Primary Sclerosing Cholangitis Companies: HighTide Biopharma, Gilead Sciences, Immunic, Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., HighTide Biopharma, Dr. Falk Pharma, Mirum Pharmaceuticals, CymaBay Therapeutics, Ipsen, Genfit, Albireo, and others

  • Key Primary Sclerosing Cholangitis Therapies: HTD 1801, GS-9674, IMU-838, Research programme-antifibrotic therapeutics, GRI-0124, QBT-002, STP707, CS0159, CM 101, Volixibat, PLN-74809 (bexotegrast), HTD1801, Norursodeoxycholic acid, Volixibat, Seladelpar, Elafibranor, A3907, and others

  • Primary Sclerosing Cholangitis Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and Primary Sclerosing Cholangitis emerging therapies

  • Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis market drivers and Primary Sclerosing Cholangitis market barriers

 

Request for Sample PDF Report for Primary Sclerosing Cholangitis Pipeline Assessment and clinical trials

 

Table of Contents

1. Primary Sclerosing Cholangitis Report Introduction

2. Primary Sclerosing Cholangitis Executive Summary

3. Primary Sclerosing Cholangitis Overview

4. Primary Sclerosing Cholangitis- Analytical Perspective In-depth Commercial Assessment

5. Primary Sclerosing Cholangitis Pipeline Therapeutics

6. Primary Sclerosing Cholangitis Late Stage Products (Phase II/III)

7. Primary Sclerosing Cholangitis Mid Stage Products (Phase II)

8. Primary Sclerosing Cholangitis Early Stage Products (Phase I)

9. Primary Sclerosing Cholangitis Preclinical Stage Products

10. Primary Sclerosing Cholangitis Therapeutics Assessment

11. Primary Sclerosing Cholangitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Primary Sclerosing Cholangitis Key Companies

14. Primary Sclerosing Cholangitis Key Products

15. Primary Sclerosing Cholangitis Unmet Needs

16 . Primary Sclerosing Cholangitis Market Drivers and Barriers

17. Primary Sclerosing Cholangitis Future Perspectives and Conclusion

18. Primary Sclerosing Cholangitis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

California spice brand From Byadgi publishes third-party lab results for every batch of its Indian spices

California spice brand From Byadgi publishes third-party lab results for every batch of its Indian spices
The Whole Collection from From Byadgi: all 10 single-origin spices in one gift set.
From Byadgi, a Fremont, California Indian spice brand, publishes third-party lab results for every batch, linked by a QR code on each pouch. Its spices and gift sets are 50% off through January 5, 2027.

Fremont, California, United States - November 13, 2026 - From Byadgi, a family-rooted Indian spice brand based in Fremont, California, publishes third-party lab results for every batch of spice it sells, with a QR code on each pouch that opens the report for that batch. Through January 5, 2027, the brand is also offering 50% off its full range of single-origin spices and spice gift sets, including Black Friday weekend, November 27 to 30.

Why lab testing matters when buying spices

Consumer Reports testing of 126 dried herbs and spices from 38 brands found that about one-third had levels of arsenic, lead and cadmium combined that raised a health concern for children who eat them regularly. In separate 2024 testing, Consumer Reports found troubling lead levels in one-third of the ground cinnamon products and cinnamon blends it checked.

From Byadgi tests every batch with a third-party lab for lead and other heavy metals, pesticide residues and microbiology, and publishes the results on its lab results page. A QR code on every pouch opens the lab report for that product, so shoppers can check the results before they cook.

What the sale covers

The 50% discount applies to every product in the From Byadgi range:

  • Single spices in 4 oz and 8 oz pouches, including Byadgi chili powder, Kashmiri chili powder, turmeric, coriander, cumin seeds, black peppercorns, whole cloves, Ceylon cinnamon and chili flakes.
  • The Starter Set, six everyday essentials for cooks new to Indian food.
  • The Chili Collection, four Indian chilies from mild to hot.
  • The Spice Shelf, every ground spice in the range.
  • The Whole Collection, all 10 spices in one gift set.
  • Trios for everyday cooking, tempering (tadka), and mild or spicy heat.


Shipping is free in the U.S. on orders over $36, and orders ship in sealed pouches from California. The brand's spice gift set guide explains which set suits which kind of cook.

From the chili capital of Karnataka

From Byadgi takes its name from Byadgi, a town in Karnataka, India, known for its deep-red chilies. The founding family has worked in the Byadgi spice trade for 40 years. Every pouch contains one ingredient, with no fillers or added colors.

"My family has worked with Byadgi chilies for 40 years," said Chaitra, founder of From Byadgi. "This holiday season we want more U.S. kitchens to cook with the real thing, and to see the lab report for every batch they buy."

Holiday sale details

  • Offer: 50% off every spice and spice gift set
  • Black Friday weekend: November 27 to November 30, 2026
  • Sale ends: January 5, 2027
  • Gift sets: Starter Set, Chili Collection, Spice Shelf, Whole Collection, Trios
  • Lab testing: every batch, third-party lab; reports linked by QR code
  • Shipping: free in the U.S. on orders over $36; ships from California
  • Where to buy: frombyadgi.co


About From Byadgi

From Byadgi is a Fremont, California brand that sells single-origin Indian spices, with its chilies sourced from Byadgi, Karnataka. Founded in 2024 by a family with 40 years in the Byadgi spice trade, the brand offers single-ingredient spices and gift sets that are lab tested every batch, with reports published online.

More information is available at frombyadgi.co.

Media Contact
Company Name: From Byadgi
Contact Person: Chaitra
Email:Send Email
Phone: 5102035072
Address:28 Geary Street Suite 650 #1004
City: San Francisco
State: CA 94108
Country: United States
Website: https://frombyadgi.co

Black Friday Perfume Dupes Go Pocket-Size as Pocket Perfume Launches Its Biggest Deal Ever: Buy 2, Get 2 Free

Black Friday Perfume Dupes Go Pocket-Size as Pocket Perfume Launches Its Biggest Deal Ever: Buy 2, Get 2 Free
Cap off: Pocket Perfume inspired by Black Opium, one of the solid perfume sticks in the Buy 2, Get 2 Free Black Friday offer.
The first-of-its-kind solid perfume, made with a 100% organic wax base and zero alcohol and inspired by the world's top designer scents, is Buy 2, Get 2 Free from Thursday, November 26 through Sunday, November 29, then 40% off from Cyber Monday, November 30, through Wednesday, December 2.

HOUSTON, TX - November 13, 2026 - This Black Friday, Pocket Perfume is running its biggest deal ever: buy two solid perfume sticks, get two free. From Thanksgiving Day, November 26, through Sunday, November 29, the offer is applied automatically at checkout with no code needed, and from Cyber Monday, November 30, through Wednesday, December 2, every stick and bundle is 40% off.

Black Friday perfume dupes usually mean another bottle that sits on your dresser, made of alcohol that fades away almost as soon as you spray it. Pocket Perfume is the first-of-its-kind solid perfume: a twist-up stick made with a 100% organic wax base and zero alcohol, in scents inspired by the top designer fragrances in the world.

Your favorite fragrances are now finally portable, for a fraction of the cost. With no alcohol to evaporate, the scent sits on the skin and stays with you, without the chemical bite of a spray. Each stick is hand-poured in Texas, about the size of a lip balm, and solid rather than liquid, so it slips into a purse, a pocket or a carry-on with nothing to leak or spill. Twist it up and swipe it across the wrist or neck like a balm, then touch up anywhere, any time. A single travel stick is $14.99. During the Black Friday sale, four cost $29.98, under $7.50 a stick.

"Fragrance has been sold the same way for a hundred years: alcohol in a glass bottle that stays on the dresser, costs a fortune and fades away in minutes. We built something that has never existed before. We are the first to put it all together: a 100% organic wax base, zero alcohol, scents inspired by the world's top designer fragrances, and a portable twist-up stick, so the scents you love most can go everywhere with you, last all day long and cost a fraction of the price. We are going to change this entire industry." -- Bryan Lantry, CEO, Pocket Perfume and Pocket Cologne

Lantry points to ChapStick as the model. "Over a century ago, lip balm came wrapped in tin foil, until somebody put it in a stick and it ended up in every pocket in America," he said. "We are taking a play straight from their book and doing the exact same thing for fragrance: a Pocket Perfume in every woman's purse and a Pocket Cologne in every man's pocket. We built this for you, the customer, and this is the most fun deal we have ever done. With the love our customers have shown this brand, there is not one doubt in my mind that it will become one of the largest, most recognizable household brands in the world. Think about it: have you ever met a woman who doesn't have a ChapStick in her purse, or walked into a store that doesn't sell one? We are going to do the same thing. This is your first exclusive look."

The collection includes more than 30 scents across warm, fresh and floral families, and sister brand Pocket Cologne carries the same sticks for men. Four sticks make a set for yourself or stocking stuffers for every woman on your list.

Black Friday and Cyber Monday Offers at a Glance

  • Thursday, November 26 to Sunday, November 29: Buy 2, Get 2 Free on every Pocket Perfume and Pocket Cologne scent
  • Monday, November 30 to Wednesday, December 2: 40% off sticks and bundles
  • Applied automatically at checkout on pocketperfume.com and pocketcologne.com; each sale starts and ends at midnight Central time
  • Custom engraved sticks, gift cases and the display case are not included


About Pocket Perfume and Pocket Cologne

Pocket Perfume and its sister brand Pocket Cologne are fragrance brands from Pocket Products LLC, based in Houston, Texas, and led by CEO Bryan Lantry. Their twist-up solid fragrance sticks pair a 100% organic wax base with scents inspired by the world's top designer fragrances, made to be carried anywhere. Learn more at pocketperfume.com and pocketcologne.com.

Media Contact Bryan Lantry, CEO Pocket Products LLC info@pocketperfume.com 585-545-5110 https://pocketperfume.com/black-friday-perfume-dupes

Media Contact
Company Name: Pocket Products LLC
Contact Person: Bryan Lantry
Email:Send Email
Phone: 585-545-5110
City: Houston
State: TX
Country: United States
Website: https://pocketperfume.com

Life Tree Anatomical Shares Census Estimates Placing Travis County at 1.39 Million Residents in 2025

Life Tree Anatomical Shares Census Estimates Placing Travis County at 1.39 Million Residents in 2025
Travis County reached an estimated 1,389,670 residents in 2025. Life Tree Anatomical - Texas Body Donation offers plain-language information on how whole body donation works in Texas.

AUSTIN, TX - November 13, 2026 - Life Tree Anatomical Texas Body Donation, a non-transplant anatomical donation organization based on North Interstate Highway 35 in Austin, is sharing U.S. Census Bureau population estimates for Travis County, along with information for Texans considering donating their body to science and for the families who may one day carry out that wish.

The figures come from the Census Bureau's Vintage 2025 population estimates for Travis County, published on the bureau's QuickFacts page.

Travis County Population Estimates

Travis County's population was an estimated 1,389,670 on July 1, 2025, in Census Bureau estimates, up 7.7 percent from an estimates base of 1,290,157 in April 2020. QuickFacts puts the share of Travis County residents under 18 at 19.7 percent, with 11.6 percent aged 65 or older.

These estimates describe the county's population. Decisions about donation are personal and are made one person at a time.

How to Register

Pre-registering is the clearest way to record a person's wishes and give family members practical instructions. Life Tree Anatomical provides an information packet and its current donation form. The steps it describes are to review the program disclosures and eligibility information, provide the requested personal and medical information, complete the required authorization documents, read the donor acknowledgement carefully before signing, and keep copies where a trusted person can find them.

A will is one legal way to make an anatomical gift, but it is not required, and the organization notes that relying only on estate documents can cause problems if they are not found quickly after death. Registering documents a person's wishes but does not guarantee that a donation will be accepted.

Who Can Donate

A donor does not need to be in perfect health. A diagnosis such as cancer, heart disease or diabetes does not by itself decide the question. Circumstances that may affect acceptance include certain contagious diseases, open wounds, autopsy, body size, severe trauma and the timing of notification. Because some donors cannot be accepted, the organization says every family should keep an alternative final-disposition plan in place.

Life Tree Anatomical's Work in Austin

Accepted donations support anatomy education, professional medical training, research and other purposes set by the donor's signed authorization. Under its placement policy, the organization offers donations to Texas-based medical schools, surgical training programs and research institutions first, and families may ask where a specific gift was placed. When return of cremated remains is selected and applicable, available cremated remains are returned to the person named in the donor's documents. Donors may amend or revoke a gift during their lifetime using a method permitted by Texas law.

The organization's website lists it as open 24 hours, and it works with donors and families across Texas.

About Life Tree Anatomical

Life Tree Anatomical is a non-transplant anatomical donation organization based in Austin, Texas, supporting medical education, surgical training and research.

Media Contact

Life Tree Anatomical - Texas Body Donation

16912 N Interstate Hwy 35, Austin, TX 78728

(512) 402-8533

https://lifetreeanatomical.com/

Sources: U.S. Census Bureau, QuickFacts, Travis County, Texas (Vintage 2025): https://www.census.gov/quickfacts/traviscountytexas

Media Contact
Company Name: Life Tree Anatomical - Texas Body Donation
Contact Person: Dennis James
Email:Send Email
Phone: (512) 402-8533
Address:16912 N Interstate Hwy 35
City: Austin
State: TX 78728
Country: United States
Website: https://lifetreeanatomical.com/

Imperium Home Remodeling & Construction Shares 2025 Census Counts of Jupiter's 28 New Single-Family Homes

Imperium Home Remodeling & Construction Shares 2025 Census Counts of Jupiter's 28 New Single-Family Homes
With Census permit counts for the town of Jupiter as context, Imperium Home Remodeling & Construction explains how its Hibiscus Street team takes a kitchen or bathroom remodel from first meeting to final walkthrough.

JUPITER, FL - November 13, 2026 - Imperium Home Remodeling & Construction, a Hibiscus Street remodeling and construction company that handles kitchen, bathroom and whole-home projects in Jupiter, is sharing U.S. Census Bureau building permit data for the town, along with guidance for homeowners planning work on an existing home.

Each year the Census Bureau's Building Permits Survey records how many new privately owned homes a local permit office approves, and this release compares the town's entries for 2024 and 2025.

New Homes Authorized in Jupiter

The town of Jupiter authorized 28 new single-family homes in 2025, with a combined reported construction value of about $42.8 million, or roughly $1.5 million per home, Building Permits Survey data show. In 2024, the town authorized 40 single-family homes valued at about $36.3 million. No units in multifamily buildings were reported in either year.

The permit survey covers new homes only. Remodels of existing houses are not part of these counts.

Renovating Versus Remodeling

The company draws a clear line between the two terms. Renovating means updating what already exists, such as new paint, replacement fixtures, refinished flooring or new countertops. Remodeling changes the structure, layout or function of a space, which can mean removing walls, moving plumbing lines or reconfiguring a kitchen. A bathroom renovation might replace the vanity and tile, while a bathroom remodel might expand the shower, relocate the toilet and add a double vanity.

How the Process Works

Imperium describes its process in four steps. The team first discusses the homeowner's goals, assesses the space and outlines a plan covering needs, budget and timeline. The homeowner then selects finishes and materials using CAD drawings and photorealistic 3D renderings. Third, the company handles permits and inspections and manages demolition, structural work and installation. Finally, the team reviews the completed work with the homeowner and provides documentation for warranties and permits.

Imperium's Work in Jupiter

The company uses its own plumbing, electrical and carpentry teams, and each project has a dedicated project manager as the homeowner's single point of contact. It limits the number of projects it takes on at the same time. Its services include kitchen remodeling, bathroom and shower remodels, custom cabinetry, general contracting, new home construction and turnkey design.

Remodeling in deed-restricted neighborhoods requires HOA approval before work begins, which the company's site says is common across many Jupiter communities, so approval timing can shape a start date. The company recommends a contingency of 15 to 20 percent for issues uncovered during a renovation, such as hidden moisture damage or outdated wiring. Its website lists Tequesta, Juno Beach and Palm Beach Gardens among the communities it serves.

About Imperium Home Remodeling & Construction

Imperium Home Remodeling & Construction is a home remodeling and construction company in Jupiter, Florida, providing remodeling, custom cabinetry, general contracting, new construction and design services.

Media Contact

Imperium Home Remodeling & Construction

228 Hibiscus St Ste 9, Jupiter, FL 33458

(772) 888-1177

https://imperiumhomes.com/

Sources: U.S. Census Bureau, Building Permits Survey, annual place data, South Region, 2025: https://www2.census.gov/econ/bps/Place/South%20Region/so2025a.txt ; 2024: https://www2.census.gov/econ/bps/Place/South%20Region/so2024a.txt

Media Contact
Company Name: Imperium Home Remodeling & Construction
Contact Person: Jason Rubio
Email:Send Email
Phone: (772) 888-1177
Address:228 Hibiscus St Ste 9
City: Jupiter
State: FL
Country: United States
Website: https://www.imperiumhomes.com

Soren Law Group Shares New York State Health Department 2023 Marriage and Annulment Data for Staten Island

Soren Law Group Shares New York State Health Department 2023 Marriage and Annulment Data for Staten Island
Soren Law Group has published a guide that pairs New York State Department of Health marriage and dissolution counts for Richmond County with what affects how long a divorce takes and when annulment applies.

STATEN ISLAND, NY - November 13, 2026 - Soren Law Group, a South Avenue family law firm that represents Staten Island residents in divorce and custody matters, is sharing New York State Department of Health vital statistics on marriages and dissolutions in Richmond County, along with plain-language information for residents considering divorce.

The guide draws on the Department of Health's 2023 Vital Statistics tables 47 and 48, the most recent published year. The department labels the data provisional.

Marriages and Dissolutions in Richmond County

Table 47 shows 3,262 marriages took place in Richmond County in 2023. June was the busiest month, with 360 ceremonies.

Annulments are rare by comparison. Table 48 lists no annulment decrees in Richmond County that year, and statewide only 36 of the 51,332 marriage dissolutions were annulments.

The figures count decrees and ceremonies. They do not predict the outcome or length of any case.

How Long a Divorce Takes

According to the firm, the length of a divorce depends on how complex the case is, whether it is contested and the workload of the court. Uncontested divorces typically take a few months. When couples disagree over child custody, property division or financial support, the process can take a year or more, especially if hearings or a trial are needed. Mediation and collaborative law can save time by resolving disputes outside of court, and the firm notes that most of its cases settle out of court.

Divorce or Annulment

A divorce ends a legal marriage. An annulment declares a marriage void, as if it never took place. In New York, annulments are granted only on specific legal grounds, such as fraud, a spouse being underage or a spouse already being married, which is consistent with how rarely they appear in the state's counts. Whether either applies depends on the circumstances.

Soren Law Group's Work on Staten Island

The firm's website says it has represented clients on Staten Island for over 20 years. Its practice areas include contested and uncontested divorce, child custody and visitation, child support and modifications, divorce mediation and collaborative law, prenuptial, postnuptial and separation agreements, and paternity and relocation cases.

The firm also points out a practical issue many people do not expect. If a person meets with a lawyer and shares private details about their case, that lawyer is generally barred from later representing the other spouse. Its guidance on finances starts with paperwork: statements for bank accounts, credit cards, loans and retirement funds, along with deeds, tax returns and insurance policies. The firm represents clients throughout Richmond County, and its areas-served page also lists Brooklyn and Manhattan.

About Soren Law Group

Soren Law Group is a family law firm in Staten Island, New York, serving Richmond County. The information in this release is general, is not legal advice and does not create an attorney-client relationship. Attorney advertising.

Media Contact

Divorce Lawyer - Soren Law Group

900 South Ave #204, Staten Island, NY 10314

(718) 815-4500

https://sorenlaw.com/

Sources: New York State Department of Health, Vital Statistics of New York State 2023, Table 47: https://www.health.ny.gov/statistics/vital_statistics/2023/table47.htm ; Table 48: https://www.health.ny.gov/statistics/vital_statistics/2023/table48.htm

Media Contact
Company Name: Divorce Law - Soren Law Group
Contact Person: Karen Soren
Email:Send Email
Phone: (718) 815-4500
Address:900 South Ave #204
City: Staten Island
State: NY 10314
Country: United States
Website: sorenlaw.com

Osteoporosis Market on the Rise: Growth Opportunities, Challenges, and Future Outlook Through 2036 | Amgen and UCB, EnteraBio, Rani Therapeutics, Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine

Osteoporosis Market on the Rise: Growth Opportunities, Challenges, and Future Outlook Through 2036 | Amgen and UCB, EnteraBio, Rani Therapeutics, Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine
The Key Osteoporosis Companies in the market include - Amgen and UCB, EnteraBio, Rani Therapeutics, Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others.

 

(Albany, New York) - November 13, 2026: DelveInsight’s “Osteoporosis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Osteoporosis, historical and forecasted epidemiology as well as the Osteoporosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Osteoporosis, offering comprehensive insights into the Osteoporosis revenue trends, prevalence, and treatment landscape. The report delves into key Osteoporosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Osteoporosis therapies. Additionally, we cover the landscape of Osteoporosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Osteoporosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Osteoporosis space.

 

To Know in detail about the Osteoporosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Osteoporosis Market Forecast

 

Some of the key facts of the Osteoporosis Market Report:

  • The Osteoporosis market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

  • In November 2026, Entera Bio reported that preparations for the Phase III clinical study of EB613 were progressing, with the activation of the first clinical site expected in late 2026. EB613 is an investigational oral PTH(1-34) tablet being developed for post

  • In September 2026, he US FDA approved Teva's DEGEVMA, a biosimilar to Xgeva (denosumab). It is indicated for certain cancer-related bone complications, giant cell tumor of bone, and hypercalcemia of malignancy. Although this approval expands denosumab biosimilar availability, DEGEVMA is not an osteoporosis treatment indication.

  • In August 2026, A 12-month Phase III study involving 279 postmenopausal women with osteoporosis evaluated KN012 against reference denosumab. Published findings demonstrated equivalent lumbar spine BMD outcomes, with comparable safety, pharmacokinetics, bone turnover markers, and immunogenicity profiles. The findings support the potential of KN012 as a biosimilar treatment option for osteoporosis.

  • In July 2026, reports highlighted Phase III findings for KN012, a denosumab biosimilar, demonstrating comparable bone mineral density outcomes to reference denosumab in postmenopausal women with osteoporosis in China. The findings support further development of biosimilar alternatives in osteoporosis management.

  • In March 2026, Entera Bio submits a streamlined Phase III Protocol to initiate a registrational program for EB613 in Postmenopausal Women with Osteoporosis; Entera commits to a 12-month extension study to run in parallel with potential NDA review.

  • In March 2026, the US FDA approved Teva Pharmaceuticals' PONLIMSI as an interchangeable biosimilar to Prolia (denosumab). It is indicated for postmenopausal women and men with osteoporosis at high risk of fractures, among other bone-related indications. The approval expands treatment options and could improve access to denosumab-based osteoporosis management.

  • In January 2026, Angita Biopharmaceuticals completes enrollment in Phase II (ARTEMIS) trial of AGA2118 for Osteoporosis treatment; topline data expected in 2027.

  • In September 2025, Shanghai Henlius Biotech and Organon announced that the U.S. FDA approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA and XGEVA, respectively, for all indications of the reference products. BILDYOS is a RANK ligand (RANKL) inhibitor indicated for osteoporosis treatment in high-risk postmenopausal women and men, glucocorticoid-induced osteoporosis, and bone mass increase in prostate and breast cancer patients receiving specific therapies. Patients with advanced kidney disease face higher risks of severe hypocalcemia, requiring expert supervision before and during treatment.

  • In September 2025, Naitive Technologies announced that it received 510(k) clearance from the U.S. FDA for its AI-driven product, OsteoSight. This software enables bone mineral density (BMD) assessment using standard X-rays, helping detect osteoporosis earlier, which is often undiagnosed until fractures occur. OsteoSight supports proactive osteoporosis management and offers growth opportunities for orthopedic practices.

  • In March 2025, the FDA approved Fresenius Kabi Biopharma's denosumab biosimilars, Conexxence and Bomyntra (denosumab-bnht), for all indications of the reference products Prolia and Xgeva, expanding access to more affordable treatments for osteoporosis, bone metastases, and other bone-related conditions.

  • In March 2025, Dr. Reddy’s Laboratories Ltd. and Alvotech announced that the FDA has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, a proposed biosimilar of Prolia® (denosumab) and Xgeva® (denosumab), developed by Alvotech.

  • In March 2025, Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) and OSENVELT® (CT-P41, denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all indications of the reference products.

  • As per the National Institute of Health Osteoporosis and Related Bone Diseases National Resource Center, in the US, more than 53 million people either already have osteoporosis or are at high risk due to low bone mass. While, the National Health Service quotes that osteoporosis affects over 3 million people in the UK, wherein more than 500,000 people receive hospital treatment for fragility fractures every year as a result of osteoporosis.

  • In osteoporosis-related comorbidities, diabetes, respiratory disease, and cardiovascular diseases contributed the most in 2024.

  • As per the International Osteoporosis Foundation (2024), it is estimated that 75 million people in Europe, in the US, and Japan are affected by osteoporosis. In Asia, osteoporosis is greatly underdiagnosed and under-treated, even in the highest-risk patients who have already fractured.

  • Key Osteoporosis Companies: Amgen and UCB, EnteraBio, Rani Therapeutics, Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others

  • Key Osteoporosis Therapies: EVENITY (romososzumab), EB613 (PTH 1-34), RT-102, Research programme, RT-102, SHR-1222, VOLT01, CT-P41, TVB-009, and others

  • The Osteoporosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteoporosis pipeline products will significantly revolutionize the Osteoporosis market dynamics.

  • As per the International Osteoporosis Foundation, Osteoporosis affected approximately 5.2% of the total population in the UK, closely aligning with the EU27+2 average of 5.6%. Among individuals aged 50 and above in the UK, it was estimated that 21.9% of women and 6.7% of men had Osteoporosis. Hip fractures are considered the most severe outcome of the disease due to their significant impact on health, mortality, and healthcare costs.

  • A study by Yoshimura et al. (2022) reported that in Japan, the prevalence of lumbar spine (L2–L4) osteoporosis was 13.6% at the initial survey (3.4% in men and 19.2% in women) and dropped significantly to 9.7% at the fourth survey (1.4% in men and 13.9% in women), with the difference being statistically significant (p < 0.01). However, no significant change was observed in the prevalence of femoral neck osteoporosis between the two surveys.

 

Osteoporosis Overview

Osteoporosis is a medical condition in which bones become weak, brittle, and more prone to fractures due to a loss of bone density and strength. It often develops silently over time and is most common in older adults, especially postmenopausal women. Common fracture sites include the hip, spine, and wrist. The condition can be managed or prevented through calcium and vitamin D intake, regular weight-bearing exercise, and medications that help strengthen bones.

 

Get a Free sample for the Osteoporosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/osteoporosis-market

 

Osteoporosis Epidemiology

The Osteoporosis epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Osteoporosis Epidemiology Segmentation:

The Osteoporosis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Prevalent Cases of Osteoporosis

  • Diagnosed Prevalent Cases of Osteoporosis

  • Gender-specific Prevalent Cases of Osteoporosis

  • Age-specific Prevalent Cases of Osteoporosis

  • Treatable Cases of Osteoporosis

 

Download the report to understand which factors are driving Osteoporosis epidemiology trends @ Osteoporosis Epidemiology Forecast

 

Osteoporosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteoporosis market or expected to get launched during the study period. The analysis covers Osteoporosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Osteoporosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Osteoporosis Therapies and Key Companies

  • EVENITY (romososzumab): Amgen and UCB

  • EB613 (PTH 1-34): EnteraBio

  • RT-102: Rani Therapeutics

  • Research programme: Lactocore

  • RT-102: Rani Therapeutics

  • SHR-1222: Jiangsu HengRui Medicine

  • VOLT01: Levolta Pharmaceuticals, Inc.

  • CT-P41: Celltrion

  • TVB-009: Teva Pharmaceuticals

 

Discover more about therapies set to grab major Osteoporosis market share @ Osteoporosis Treatment Landscape

 

Osteoporosis Market Drivers

  • Rising Prevalence of Osteoporosis: The increasing global geriatric population, growing life expectancy, and rising incidence of age-related bone disorders are driving demand for effective osteoporosis treatment and management.

  • Increasing Awareness and Early Diagnosis: Growing awareness of bone health, expanding screening initiatives, and the adoption of bone mineral density (BMD) testing are supporting early diagnosis and treatment initiation.

  • Advancements in Novel Therapeutics: The development of innovative therapies, including anabolic agents, monoclonal antibodies, and next-generation bone-forming drugs, is expanding treatment options for osteoporosis patients.

  • Growing Focus on Fracture Prevention: Increasing emphasis on preventing osteoporosis-related fractures, particularly hip and vertebral fractures, is encouraging the adoption of effective pharmacological interventions.

  • Expanding Clinical Pipeline and R&D Investments: Rising investments in clinical research and the development of novel drugs with improved efficacy, safety, and dosing convenience are creating new growth opportunities in the osteoporosis market.

 

Osteoporosis Market Barriers

  • High Treatment Costs: The cost of advanced biologics, injectable therapies, diagnostic procedures, and long-term disease management can limit treatment accessibility, particularly in developing economies.

  • Lack of Awareness and Underdiagnosis: Limited awareness of osteoporosis risk factors, inadequate screening, and delayed diagnosis often prevent timely intervention, increasing the risk of severe fractures.

  • Adverse Effects Associated with Existing Therapies: Potential complications associated with long-term osteoporosis treatments, including atypical femoral fractures, osteonecrosis of the jaw, and gastrointestinal adverse events, may affect treatment adherence.

  • Poor Treatment Compliance: The requirement for prolonged treatment, complex dosing schedules, and inadequate patient adherence can reduce therapeutic effectiveness and negatively impact disease management.

  • Regulatory and Clinical Development Challenges: The need for long-term clinical studies to demonstrate fracture risk reduction, along with stringent regulatory requirements and safety monitoring, can increase development costs and delay the introduction of novel therapies.

 

Scope of the Osteoporosis Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Osteoporosis Companies: Amgen and UCB, EnteraBio, Rani Therapeutics, Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others

  • Key Osteoporosis Therapies: EVENITY (romososzumab), EB613 (PTH 1-34), RT-102, Research programme, RT-102, SHR-1222, VOLT01, CT-P41, TVB-009, and others

  • Osteoporosis Therapeutic Assessment: Osteoporosis current marketed and Osteoporosis emerging therapies

  • Osteoporosis Market Dynamics: Osteoporosis market drivers and Osteoporosis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Osteoporosis Unmet Needs, KOL’s views, Analyst’s views, Osteoporosis Market Access and Reimbursement

 

To know more about Osteoporosis companies working in the treatment market, visit @ Osteoporosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Osteoporosis Market Report Introduction

2. Executive Summary for Osteoporosis

3. SWOT analysis of Osteoporosis

4. Osteoporosis Patient Share (%) Overview at a Glance

5. Osteoporosis Market Overview at a Glance

6. Osteoporosis Disease Background and Overview

7. Osteoporosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Osteoporosis

9. Osteoporosis Current Treatment and Medical Practices

10. Osteoporosis Unmet Needs

11. Osteoporosis Emerging Therapies

12. Osteoporosis Market Outlook

13. Country-Wise Osteoporosis Market Analysis (2022–2036)

14. Osteoporosis Market Access and Reimbursement of Therapies

15. Osteoporosis Market Drivers

16. Osteoporosis Market Barriers

17. Osteoporosis Appendix

18. Osteoporosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services